![]() |
市場調查報告書
商品編碼
1279673
2023-2030 年全球乳房再造市場Global Breast Reconstruction Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球乳房再造市場預計將實現利潤豐厚的增長,到 2022 年將達到 5.7433 億美元,到 2030 年將達到 9.343 億美元。 預計該市場在預測期內(2023-2030 年)的複合年增長率為 6.4%。
乳房重建術使用多種整形外科技術使乳房在乳房切除術後恢復到接近正常的狀態。 植入物重建和皮瓣重建是乳房重建的兩種主要類型。 在植入重建中,乳房植入物用於創建新的乳房小丘。 皮瓣(或自體)重建使用從身體另一部分取出的患者自身組織來創建新的乳房。
意識的提高歸功於獨立機構和市場進入者的行動。 例如,2021 年 10 月 22 日,植入物製造商 AbbVie 將發起一場展示重建可能性的活動。 通過新的“你的力量”活動,這家乳房植入物製造商希望改變這種狀況。 該活動頌揚患者的勇氣和內在毅力,並教育他們了解乳房重建的選擇。 雖然該活動沒有品牌,但該公司的乳房再造產品包括組織擴張器、植入物輸送套管和 Natrelle 品牌植入物。
此外,為了提高人們對乳房再造的認識,塔塔紀念中心舉辦了一場名為“再造與癌症護理”的會議。 由於上述因素,預計乳房再造市場將在整個預測期內處於領先地位。
3D 打印植入物的開發可能為商業擴張帶來可觀的前景。 例如,2023 年 4 月 6 日,乳房植入物將由 CollPlant 和 Stratasys 進行生物打印。 該公司與 CollPlant 合作,具有利用生物打印技術轉變醫療保健並改善接受隆胸和修復治療患者生活的巨大潛力。
CollPlant 和 Stratasys 簽訂了聯合開發和商業化協議,以推進生物打印技術的發展。 該合作夥伴關係將結合 Stratasys 基於 P3 技術的生物打印機與 CollPlant 基於 rhCollagen 的生物墨水。 可編程光聚合,稱為 P3,是數字光處理 (DLP) 技術的發展,旨在大規模製造有用的最終用途組件。
市場暫時受到 COVID-19 大流行的影響,其中大部分處於爆發的早期階段。 限制和停工導致正在進行和預定的外科手術被推遲或取消,阻礙了乳房植入物市場的擴張。 然而,在美國女性中 COVID-19 流行期間,人們對外觀的興趣和意識有所提高,包括隆胸和植入物。 因此,市場有望從 COVID-19 大流行的影響中恢復和發展。
由於俄烏戰爭在該地區的滲透率較低且缺乏主要市場參與者,因此估計對全球乳房再造市場的影響較小。 然而,在預測期內,原材料、試驗產品和設備的進出口影響預計對全球乳房再造市場影響不大。
得益於 Breast Advocate 應用程序,人工智能有望對全球乳房再造市場產生積極影響,Breast Advocate 應用程序是世界上第一個用於乳房再造和癌症手術的共享決策工具。 這個應用程序是一個免費的應用程序,它允許任何被診斷出患有乳腺癌或有患乳腺癌風險的人在他們的手術選擇中有發言權。 這個應用程序是由乳腺癌醫生和患者活動家共同創建的。
The global breast reconstruction market reached US$ 574.33 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 934.30 million by 2030. The market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).
Breast reconstruction uses several plastic surgical techniques to return a breast to a state that is very close to normal after a mastectomy. Implant-based reconstruction and flap reconstruction are the two main types of breast reconstruction. Breast implants are used in implant reconstruction to create a new breast mound. Flap (or autologous) reconstruction creates a new breast using the patient's own tissue from another area of the body.
The increase in awareness can be attributed to actions made by independent bodies and market participants. For instance, on October 22, 2021, AbbVie, an implant manufacturer, develops a campaign to showcase reconstruction possibilities. With its new "Power of You" campaign, the breast implant manufacturer hopes to change that. The initiative honors patients' bravery and inner fortitude while educating them on their options for breast reconstruction. Although the campaign is unbranded, the company's breast reconstruction products include tissue expanders, implant delivery sleeves, and Natrelle-branded implants.
Additionally, to raise awareness of breast reconstruction, Tata Memorial Centre organized a conference titled Reconstruction and Cancer Care: Enhancing Quality Living with and Beyond Cancer on February 17, 2022. As a result of the aforementioned factors, the breast reconstruction market is anticipated to lead throughout the forecast period.
The development of 3D-printed implants may present considerable prospects for commercial expansion. For instance, on April 06, 2023, Breast implants will be bioprinted by CollPlant and Stratasys. The company has a significant chance to use bioprinting to alter healthcare and better the lives of patients undergoing breast augmentation or repair treatments thanks to its cooperation with CollPlant.
To advance the development of bioprinting technology, CollPlant, and Stratasys inked a combined development and commercialization agreement. The collaboration will pair Stratasys' P3 technology-based bioprinter with CollPlant's rhCollagen-based bio-inks. Programmable PhotoPolymerization, also known as P3, is a development of digital light processing (DLP) technology intended for the bulk manufacturing of useful end-use components.
The market was temporarily impacted by the COVID-19 pandemic, mostly during the pandemic's early stages. The ongoing and scheduled surgical procedures were postponed or canceled as a result of the limitations and lockout, which hampered the expansion of the breast implant market. However, during the COVID-19 pandemic among women in the United States, interest and growing awareness regarding physical appearance, including breast augmentation and implants, increased. As a result, the market is anticipated to rebound from the COVID-19 pandemic's effects and develop.
The Russia-Ukraine is estimated to have a minimal impact on the global breast reconstruction market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test products, and devices is anticipated to have little influence over the global Breast reconstruction market in the forecast period.
Artificial intelligence is anticipated to impact the global breast reconstruction market positively owing to the Breast Advocate app being the first shared decision-making tool for breast reconstruction and cancer surgery in the world. It is a free app that gives anybody with a breast cancer diagnosis or at risk of getting breast cancer a voice in the choices made about their surgery. It was co-created by breast cancer doctors and patient activists.
The Round Shape Segment is Estimated to Hold a Majority of the Breast Reconstruction Market Share During the Forecast Period.
The round shape holds about 56% of the total breast reconstruction market in the forecast period owing to the acceptance of new products by different permitting bodies. The dominance can be due to the increase in product announcements, the FDA's regular updates on the safety of breast implants, and the execution of several clinical investigations.
For instance, GC Aesthetics will introduce the PERLE, a new generation of round silicone breast implants, in May 2021. In order to ensure that patients undergoing breast implant surgery have enough information, the U.S. FDA amended its safety guidelines for breast implants in October 2021 and prohibited the sales and distribution of breast implants. Therefore, round-shaped breast implants are anticipated to experience significant growth as a result of the aforementioned factors.
Asia Pacific is Estimated to Hold the Second-largest Share of the Global Breast Reconstruction Market During the Forecast Period.
For instance, the NCBI data revealed that there were approximately 303,600 new instances of breast cancer and 70,400 fatalities from the disease in China. Furthermore, according to a similar source, the incidence rate and mortality rate in China are predicted to rise by 2030 due to changing demographics and risks. More than 76.5% of women preferred breast reconstruction following mastectomy, according to research by a similar source.
The major global players in the market include: Allergan Plc, Sientra, Inc, IDEAL IMPLANT INCORPORATED, Johnson & Johnson, Establishment Labs S.A., GC Aesthetics, Groupe Sebbin SAS, Ideal Implant Incorporated, Laboratoires Arion, and Mentor Worldwide LLC, among others.
The global Breast reconstruction market report would provide approximately 69 tables, 66 figures, and 195 Pages.
LIST NOT EXHAUSTIVE